Rachidi, N. | IICIMED

Rachidi, N.

Publications

P300

RSC Med. Chem. 2025, 16, 3746–3763. 

 Pharmacophore-guided optimization of the hit compound CTN1122 in the design of promising imidazo[1,2-a]pyrazine derivatives targeting the casein kinase 1 for antileishmanial therapy

Tisseur, L. | Logé, C. | Cojean, S. | Gassama, K. | Karcher, L. | Pagniez, F. | Cavé, C. | Bernadat, G. | Loiseau, P. M. | Bach, S. | Thiéfaine, J. | Bonnet, J. | Picot, C. | Tomasoni, C. | Leclercq, O. | Baratte, B. | Robert, T. | Le Pape, P. | Rachidi, N. | Bazin, M.-A. | Marchand, P.

https://doi.org/10.1039/D5MD00257E

P290

ChemMedChem. 2025, 20, e202400862.

Investigating the C2 modulation of the imidazo[1,2-a]pyrazine-based hit compound CTN1122: synthesis, in vitro antileishmanial activity, cytotoxicity and casein kinase 1 inhibition.

Tisseur, L. | Cojean, S. | Gassama, K. | Logé, C. | Pagniez, F. | Cavé, C. | Bernadat, G. | Loiseau, P.M. | Bach, S. | Thiéfaine, J. | Picot, C. | Tomasoni, C. | Leclercq, O. | Baratte, B. | Robert, T. | Le Pape, P. | Rachidi, N. | Bazin, M.-A. | Marchand, P.

https://doi.org/10.1002/cmdc.202400862

P231

Eur. J. Med. Chem. 2021, 210, 112956.

In vitro identification of imidazo[1,2-a]pyrazine-based antileishmanial agents and evaluation of L. major casein kinase 1 inhibition.

Bazin, M.-A. | Cojean, S. | Pagniez, F. | Bernadat, G. | Cavé, C. | Ourliac-Garnier, I. | Nourrisson, M.-R. | Morgado, C. | Picot, C. | Leclercq, O. | Baratte, B. | Robert, T. | Späth, G.F. | Rachidi, N. | Bach, S. | Loiseau, P.M. | Le Pape, P. | Marchand, P.

doi: 10.1016/j.ejmech.2020.112956

P108

 Eur. J. Med. Chem., 2012, 58, 543-556. 

Synthesis and biological evaluation of 2,3-diarylimidazo[1,2-a]pyridines as antileishmanial agents.

Marhadour, S. | Marchand, P. | Pagniez, F. | Bazin, M.-A. | Picot, C. | Lozach, O. | Ruchaud, S. | Antoine, M. | Meijer, L. | Rachidi, N. | Le Pape, P.

Autres publications scientifiques

Brevets

Thèse